SeaStar Medical Q3 net revenue rises on QUELIMMUNE adoption
Overview
Healthcare device maker's Q3 net revenue rose yr/yr on higher QUELIMMUNE adoption
Company posted Q3 net loss of $4.5 mln as R&D expenses increased for clinical trials
Outlook
Company expects NEUTRALIZE-AKI trial enrollment to complete by mid-year 2027
Result Drivers
QUELIMMUNE ADOPTION - Revenue growth attributed to expanded use of QUELIMMUNE therapy for pediatric sepsis-associated AKI
REGULATORY PROGRESS - Fulfillment of FDA post-approval SAVE Registry requirements may increase hospital access to QUELIMMUNE
R&D SPENDING - Higher research and development expenses driven by increased clinical research activities for NEUTRALIZE-AKI trial and SCD development
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $635,000 | $450,500 (2 Analysts) |
Q3 Loss Per Share | $1.03 | ||
Q3 Net Loss | $4.53 mln | ||
Q3 Operating Expenses | $5.17 mln | ||
Q3 Operating Income | -$4.58 mln |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for SeaStar Medical Holding Corp is $10.00, about 426.3% above its November 10 closing price of $1.90
Reuters Recommended Reads
Nov 10 - Opus Genetics Q3 revenue falls and misses analyst estimates
Nov 10 - Cellectar Biosciences Q3 net loss widens on higher R&D costs
Nov 10 - Humacyte Q3 net loss narrows on lower expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)